Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
Editor-in-Chief
HCV Advocate
HBV Advocate

Tuesday, October 23, 2012

Hepatitis B treatment in younger patients remains complicated

NEW ORLEANS — Hepatitis B is a global disease, and treatment remains elusive, particularly in the pediatric population, according to a presenter here at the 2012 AAP National Conference and Exhibition.
Judith A. O’Connor, MD, who is a pediatric gastroenterologist at the University of Oklahoma Health Sciences Center, said although treatment of HBV can be tricky in younger patients, it is crucial because this illness has a profound effect on their lives.

 O’Connor said all of the treatment options for HBV have limitations. Interferon’s assets include that these medications only require a limited time frame for treatment, and they have the best antibody responses, but, on the downside, they can be painful, they require three-times-a-week dosing, and this is an expensive treatment, although it is only for 1 year.

Read more..

No comments:

Post a Comment